Neville Rodie & Shaw Inc. Sells 46,800 Shares of Boston Scientific Corporation $BSX

Neville Rodie & Shaw Inc. trimmed its holdings in Boston Scientific Corporation (NYSE:BSX) by 72.3% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 17,970 shares of the medical equipment provider’s stock after selling 46,800 shares during the quarter. Neville Rodie & Shaw Inc.’s holdings in Boston Scientific were worth $767,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter valued at about $26,000. Swiss RE Ltd. bought a new stake in shares of Boston Scientific in the fourth quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Boston Scientific during the fourth quarter valued at approximately $26,000. Sfam LLC bought a new position in Boston Scientific during the fourth quarter valued at approximately $29,000. Finally, Eagle Bay Advisors LLC purchased a new stake in Boston Scientific in the fourth quarter worth approximately $30,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In related news, Director Cheryl Pegus acquired 1,770 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David C. Habiger acquired 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares in the company, valued at $776,057.76. This trade represents a 19.35% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 14,800 shares of company stock worth $781,412 over the last quarter. 0.34% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Up 1.5%

BSX opened at $49.14 on Wednesday. The firm’s 50 day simple moving average is $45.78 and its two-hundred day simple moving average is $61.39. The company has a market capitalization of $73.04 billion, a PE ratio of 19.90, a PEG ratio of 1.06 and a beta of 0.56. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.36%. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the previous year, the firm posted $0.75 EPS. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its Board of Directors has initiated a share buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of research firms have commented on BSX. Leerink Partners set a $60.00 target price on shares of Boston Scientific in a research report on Thursday, July 30th. Zacks Research downgraded Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Evercore set a $65.00 price objective on Boston Scientific in a report on Monday, July 6th. Wolfe Research cut Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. Finally, Needham & Company LLC lowered their target price on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, July 8th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.